CIK 0001653087
- Accelerated filer
- Smaller reporting company
Alector, Inc.
Sign in to watch- Ticker
- ALEC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 822933343
- Phone
- +1 415-231-5660
- Business address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Alector LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $296,087
- in 3 filings
Net −$296,087. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-03 | Rosenthal Arnon Chief Executive Officer | Sale | −104,347 | $1.12 | $117K | 2,420,040 |
| 2025-09-02 | Wong-Sarad Grace Principal Accounting Officer | Sale | −5,910 | $2.50 | $15K | 103,448 |
| 2025-09-02 | Berkley Neil Lindsay Principal Financial Officer | Sale | −15,842 | $2.50 | $40K | 346,570 |
| 2025-09-02 | Kenkare-Mitra Sara President and Head of R&D | Sale | −23,638 | $2.50 | $59K | 543,339 |
| 2025-09-02 | Rosenthal Arnon Chief Executive Officer | Sale | −51,562 | $2.50 | $129K | 2,350,220 |
| 2025-08-26 | Hammond Paula Director | Sale 10b5-1 | −14,000 | $2.36 | $33K | 74,909 |
| 2025-06-20 | Yaffe Kristine Director | Sale 10b5-1 | −1,000 | $1.44 | $1K | 95,409 |
| 2025-06-02 | GRASSO MARC Chief Financial Officer | Sale | −16,488 | $1.34 | $22K | 296,072 |
| 2025-06-02 | Kenkare-Mitra Sara President and Head of R&D | Sale | −23,890 | $1.34 | $32K | 512,252 |
| 2025-06-02 | Rosenthal Arnon Chief Executive Officer | Sale | −52,087 | $1.34 | $70K | 2,414,657 |
| 2025-03-03 | GRASSO MARC Chief Financial Officer | Sale | −18,091 | $1.47 | $27K | 312,560 |
| 2025-03-03 | Kenkare-Mitra Sara President and Head of R&D | Sale | −29,073 | $1.47 | $43K | 536,142 |
| 2025-03-03 | Rosenthal Arnon Chief Executive Officer | Sale | −40,330 | $1.47 | $59K | 2,466,744 |
| 2025-03-03 | Romano Gary Chief Medical Officer | Sale | −16,306 | $1.47 | $24K | 332,977 |
| 2024-12-02 | GRASSO MARC Chief Financial Officer | Sale | −16,489 | $2.52 | $42K | 330,651 |
| 2024-12-02 | Rosenthal Arnon Chief Executive Officer | Sale | −52,172 | $2.52 | $131K | 2,507,074 |
| 2024-12-02 | Kenkare-Mitra Sara President and Head of R&D | Sale | −26,500 | $2.52 | $67K | 565,215 |
| 2024-12-02 | Romano Gary Chief Medical Officer | Sale | −14,892 | $2.52 | $38K | 349,283 |
| 2024-09-03 | GRASSO MARC Chief Financial Officer | Sale | −7,297 | $4.88 | $36K | 130,740 |
| 2024-09-03 | Rosenthal Arnon Chief Executive Officer | Sale | −26,499 | $4.88 | $129K | 1,948,746 |
Page 2 of 13 · 249 trades